Whalesbook
China's drug regulator halts sales of Sun Pharma's dementia treatment, citing critical production flaws, underscoring persistent quality control issues for the Indian pharmaceutical giant.
The National Medical Products Administration (NMPA) in China has ordered an immediate cessation of imports, sales, and usage of Sun Pharmaceutical Industries' rivastigmine hydrogen tartrate capsules, a medication utilized in treating dementia associated with Alzheimer's disease. Announced on Monday, January 26, 2026, the ban stems from a recent remote inspection that identified significant shortcomings in the company's manufacturing operations. Specific deficiencies noted include inadequate measures for preventing contamination and failures in the quality management department's adherence to duties.
China's Regulatory Crackdown on Sun Pharma
The NMPA's directive represents a critical market exclusion for Sun Pharma within one of the world's largest healthcare markets. The banned medication, rivastigmine hydrogen tartrate capsules, is recognized for its role in managing cognitive decline in dementia patients in China, a segment experiencing growing demand due to an aging population [10, 12, 20]. The regulator's findings point to systemic failures in maintaining production integrity and quality oversight.
Echoes of Past cGMP Violations
This regulatory action in China is shadowed by a pattern of similar compliance issues faced by Sun Pharma globally. In 2024, the U.S. Food and Drug Administration (FDA) issued a warning letter to Sun Pharma, citing "significant violations" of Current Good Manufacturing Practice (cGMP) regulations. These violations were linked to the same production facility in India that is now under scrutiny by China's NMPA [3, 11, 17]. The FDA's findings detailed inadequate equipment cleaning and maintenance, cross-contamination risks, and insufficient investigations into batch failures and discrepancies. Specific issues included stagnant liquid found in equipment used for multiple drug products and improper handling of out-of-specification laboratory results, raising profound concerns about the safety and quality of drugs manufactured at the site [11, 17].
Furthermore, the FDA noted repeated violations across multiple Sun Pharma facilities, suggesting a broader issue with management oversight and the effectiveness of its overall quality system [11, 17, 24, 39]. These recurring problems have led to import alerts, barring shipments from specific facilities into the U.S. market, except under specific exemptions for drug shortages [23, 39].
Market Impact and Broader Context
Sun Pharmaceutical Industries, India's largest drugmaker by revenue, faces potential reputational damage and financial repercussions from this significant market exclusion. The company has not yet provided an official comment, leaving investors to weigh the implications for future revenue streams and operational costs associated with remediation efforts. As of January 23, 2026, Sun Pharma's market capitalization stood at approximately ₹3.91 lakh crore, with its shares trading around ₹1,631.90, reflecting a Price-to-Earnings (P/E) ratio in the range of 33-37 [4, 5, 16, 30].
The company operates within the Indian pharmaceutical sector, globally recognized as the "pharmacy of the world" [7, 18]. However, the sector also faces considerable regulatory scrutiny. While Indian pharmaceutical companies are major global suppliers, particularly of generic drugs, they have experienced a higher percentage of adverse outcomes in FDA inspections compared to other regions [24, 28]. This situation highlights the critical need for robust quality control and compliance to maintain trust with international regulatory bodies.
The Chinese market for dementia treatments is substantial and growing, projected to reach over $2.1 billion by 2030 [10, 20]. Sun Pharma's ability to swiftly address the quality concerns raised by the NMPA and the FDA will be paramount in regaining access to this vital market and reinforcing investor confidence in its global manufacturing capabilities.